Director, Corporate Accounting

The Role: 

We are seeking a highly collaborative and hands-on Director, Corporate Accounting to lead the Company’s core accounting operations as we transition to life as a public biotechnology company with an ongoing Phase 3 clinical trial. 

This role will oversee the general ledger, monthly close, and financial reporting support processes while building scalable infrastructure to support public company requirements. The Director will play a key role in strengthening internal controls, participating in the build-out of SOX compliance, and enhancing the effectiveness of our ERP and close-related systems. We are seeking a forward-thinking leader who embraces technology, automation, and emerging AI-enabled capabilities to drive scalability, strengthen controls, improve operational efficiency, and enable a more data-driven accounting organization. 

This leader will manage a small team and must combine strong technical expertise with a detail-oriented, roll-up-your-sleeves approach and a mindset focused on process optimization, system leverage, and continuous improvement. 

Here's how you will contribute:

• Lead the monthly, quarterly, and annual close processes, ensuring timely, accurate, and well-documented financial results, including oversight of the general ledger, journal entries, account reconciliations, accruals, and variance analysis.  

• Manage and develop a high-performing accounting team by providing mentorship, structure, accountability, and opportunities for professional growth within a collaborative environment.  

• Build and scale accounting processes, systems, and controls to support the Company’s evolution as a newly public biotech company, including optimization of NetSuite and related close/reporting tools to enhance automation, reporting capabilities, workflow efficiency, and data integrity.  

• Champion the evaluation and adoption of technology, automation, and AI-enabled solutions that enhance the effectiveness, scalability, and efficiency of accounting processes, internal controls, financial reporting support, and close activities, while maintaining appropriate governance, accuracy, and compliance standards. 

• Partner cross-functionally with FP&A, Clinical Operations, R&D, Procurement, and Legal to ensure accurate accounting for clinical trial expenses and other key operational activities, including leading the Phase 3 clinical trial accrual process and related financial analyses.  

• Support SEC reporting and public company compliance requirements in collaboration with the technical accounting and SEC reporting teams, including the design and implementation of ICFR and SOX-compliant processes and documentation.  

• Ensure audit readiness and serve as a key liaison with external auditors to support quarterly reviews, annual audits, and continuous process improvements across the accounting function. 

The Ideal Candidate will have:

• Bachelor’s degree in Accounting or Finance; CPA strongly preferred. 

• 10+ years of progressive accounting experience, including public company or pre-IPO experience. 

• Big 4 public accounting experience preferred. 

• Strong understanding of U.S. GAAP and general ledger accounting processes. 

• Experience with NetSuite required; familiarity with close management and ancillary financial systems preferred. 

• Experience in biotechnology, life sciences, or R&D-intensive environments preferred. 

• Experience participating in SOX implementation or operating in a SOX-compliant environment. 

• Demonstrated leadership experience managing and developing direct reports. 

• Highly detail-oriented with strong analytical and problem-solving skills. 
• Ability to operate effectively in a fast-paced, evolving environment. 

Location:   

Somerville, MA. This role is part of a highly collaborative team environment that balances in-person collaboration with some hybrid flexibility, including 4 onsite days per week. 

Who Will Love This Job:

A hands-on accounting leader who enjoys building and scaling processes, thrives in a fast-paced and evolving environment, and is energized by the opportunity to help shape the accounting infrastructure of a growing public biotechnology company. You'll enjoy this role if you are equally passionate about technical accounting excellence, developing people, driving continuous improvement, and leveraging technology and automation to modernize how work gets done.

#LI-KD1

About Generate Biomedicines

We are a clinical-stage generative biology company pioneering the AI revolution in drug design and development. We are advancing a new approach to drug creation—one grounded in the ability to design proteins with defined biological intent. By integrating machine learning with large-scale experimentation, this approach aims to reduce the uncertainty, time, and cost associated with developing protein-based medicines.

Founded in 2018, we are advancing a growing pipeline of clinical and preclinical programs across multiple disease areas and protein modalities. By unifying computational design and clinical development within a single operating model, we translate this approach into clinical-stage programs and are leading a shift from traditional drug discovery toward systematic drug generation.

At Generate:Biomedicines, we collaborate across disciplines in new ways to invent and innovate. We bring diverse perspectives to a shared goal of delivering better medicines to patients in need, faster, guided by our values and leadership behaviors.

Generate:Biomedicines is committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

Recruitment & Staffing Agencies: Generate:Biomedicines does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Generate:Biomedicines or its employees is strictly prohibited unless contacted directly by the Company’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Generate:Biomedicines and the Company will not owe any referral or other fees with respect thereto.